Navigation Links
Taking Chemo Drug Continuously Delayed Lung Cancer's Return
Date:6/5/2011

By Amanda Gardner
HealthDay Reporter

SUNDAY, June 5 (HealthDay News) -- While most patients with advanced lung cancer only take four courses of two chemotherapy drugs and then stop until recurrence occurs, continuing treatment with one of those drugs may delay return of the deadly disease, new research suggests.

The results are preliminary, but Spanish scientists report that staying on Alimta (pemextrexed) delayed recurrence of the disease.

"This is the first trial with what looks like a positive outcome where you continue the same treatment," said Dr. Neal Ready, a professor of medicine at the Duke Cancer Institute in Durham, N.C. "All the other positive trials in the past switched chemotherapy regimens, so this is a true 'maintenance' approach" in that doctors maintained the patients on the same drug.

Although overall survival data is not yet in, "if it all bears out and that looks good, this would influence medical oncologists to continue treatment after the standard combination of two chemotherapies at the same time," Ready said.

The findings, which were presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago, was funded by Lilly, which makes Alimta.

In this study, almost 1,000 patients with advanced nonsquamous non-small cell lung cancer were given a typical four courses of Alimta and cisplatin. The 539 patients who saw their disease stabilize were then randomly chosen to receive Alimta or a placebo.

Participants taking Alimta lived an average of 4.1 months without a disease recurrence compared to 2.8 months in the placebo group.

"There was a decrease of 38 percent in the risk of progression, which we believe is clinically significant and may support the use of this in a clinical context," said study author Dr. Luis Paz-Ares, chair of oncology at Seville University Hospital in Seville, Spain, who spoke at a Sunday news conference.

Side effects were about the same as those seen in previous trials of Alimta, with the only significant increases in problems being fatigue, anemia and low white blood cell count.

But in all those cases, the incidence was lower than 5 percent, Paz-Ares said.

According to Lilly, the cost of Alimta varies depending up on the patient's size but is about $4,000 per cycle wholesale.

When asked if oncologists would be likely to prescribe this medication given the possibly prohibitive cost, Dr. Mark G. Kris, moderator of the press conference and chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York City, said that he thought they would, at least for patients in which the drug worked and was tolerable.

"The benefit would be worth the spending for people who get a benefit," he said.

Ready believes that doctors' willingness to use the drug will ultimately depend on seeing the overall survival results which, said Paz-Ares, "may be available in the near future."

The American Cancer Society reports that lung cancer is the leading cause of cancer death among both men and women, killing more people than colon, breast, and prostate cancers combined. The chance that a man will develop lung cancer is about one in 13; for a woman, about one in 16. While the estimates include both smokers and non-smokers, for smokers the risk is much higher.

Research presented at medical meetings should be considered preliminary until it is published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute has more on lung cancer.

SOURCES: Neal Ready, M.D., Ph.D., professor, medicine, Duke Cancer Institute, Durham, N.C.; June 5, 2011, news conference with Luis Paz-Ares, M.D., Ph.D., chair, oncology, Seville University Hospital, Seville, Spain; Mark G. Kris, M.D., chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study
2. No increase in severe cardiovascular events for children, adolescents taking ADHD medications
3. Taking additional selenium will not reduce cancer risk
4. Women Taking Calcium Supplements May Risk Heart Health, Researchers Say
5. Taking Responsibility for Own Health Often Not Enough
6. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
7. Taking tamoxifen to prevent breast cancer can save lives and money
8. Follow-Up Deemed Lacking for People Taking Opioids
9. Taking Short Breaks From Sitting May Help Waistline and Heart
10. PSA test better predicts cancer in men taking prostate-shrinking drug
11. Patients may not have to stop taking anti-platelets for some surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Taking Chemo Drug Continuously Delayed Lung Cancer's Return
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... and updated its hallmark resource, Infusion Therapy Standards of Practice, to include vascular ... vein illumination with an estimated 85% share of the market, facilitates adherence to ...
(Date:2/11/2016)... ... 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment to ... support of a local boy named Barrett, who has been fighting ALL leukemia for ... rally support for, all local families dealing with childhood cancer. Information on how to ...
(Date:2/11/2016)... ... 11, 2016 , ... Be Well Medical Group (Be Well) is ... Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group ... in the convenience of their homes, offices or at the practices’ local office. It ...
(Date:2/11/2016)... ... ... Husted Kicking has completed its Third Annual Husted Kicking College ... 2016 according to kicking coach Michael Husted. , “This event serves as an official ... Indianapolis,” says Husted. “The NFL uses a third party organization to select players for ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... 2016   Genomic Health, Inc. (Nasdaq: GHDX ) ... year ended December 31, 2015. --> ... 2015, compared with $69.1 million in the fourth quarter of 2014, ... increased 9 percent compared with the same period in the prior ... was $63.9 million in the fourth quarter of 2015, an increase ...
Breaking Medicine Technology: